| Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value |
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed an investor presentation with the Securities and Exchange Commission ("SEC") in connection with its 2025 Annual Meeting of Stockholders to be held on June 11, 2025. |
prnewswire.com |
2025-05-12 11:30:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why |
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-08 17:00:39 |
Czytaj oryginał (ang.) |
| Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum |
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement in response to the investor presentation issued by Deep Track Capital ("Deep Track"): Deep Track's investor presentation demonstrates that Deep Track fundamentally does not understand how to run a successful commercial stage biotechnology company. |
prnewswire.com |
2025-05-07 20:45:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript |
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded. |
seekingalpha.com |
2025-05-06 23:34:11 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates |
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago. |
zacks.com |
2025-05-06 22:15:36 |
Czytaj oryginał (ang.) |
| Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs |
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. |
prnewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits |
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatitis B virus Findings released during Hepatitis Awareness Month underscore the importance of public education to address misunderstandings about hepatitis B and raise awareness of the Centers for Disease Control and Prevention (CDC) universal recommendation that eligible adults over 19 receive the hepatitis B vaccine Results will be discussed with a panel of hepatitis B experts during the May 27th LinkedIn Live event EMERYVILLE, Calif. , May 1, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the results of the Hepatitis B Perceptions and Insights Survey conducted by The Harris Poll, which found that Americans underestimate the serious consequences of hepatitis B and are largely unaware of the role vaccination plays in helping to prevent these consequences – including liver cancer. |
prnewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy |
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders ("Annual Meeting") urging stockholders to vote the GOLD proxy card "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun. |
prnewswire.com |
2025-04-29 11:30:00 |
Czytaj oryginał (ang.) |
| Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 |
EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. |
prnewswire.com |
2025-04-22 20:00:00 |
Czytaj oryginał (ang.) |
| Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders |
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.53% of the Company's outstanding shares, today announced that it has filed a definitive proxy statement in connection with its nomination of four highly qualified candidates for election to the Company's Board of Directors (the “B. |
businesswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders |
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif. , April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on June 11, 2025. |
prnewswire.com |
2025-04-17 11:15:00 |
Czytaj oryginał (ang.) |
| Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer |
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares. Today Deep Track commented on the Company's disclosure that the Board of Directors (the “Board”) has rejected a settlement proposal in connection with its nomination of four highly qualif. |
businesswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| Dynavax Files Preliminary Proxy Statement |
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Annual Meeting"). |
prnewswire.com |
2025-04-03 21:40:00 |
Czytaj oryginał (ang.) |
| Why Dynavax Technologies (DVAX) Stock Might be a Great Pick |
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-03-20 13:45:26 |
Czytaj oryginał (ang.) |
| Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase |
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction EMERYVILLE, Calif. , March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions"). |
prnewswire.com |
2025-03-06 08:00:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share |
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030. |
seekingalpha.com |
2025-03-03 19:58:06 |
Czytaj oryginał (ang.) |
| Dynavax to Participate in Upcoming Investor Conferences |
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. |
prnewswire.com |
2025-02-25 18:10:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet |
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-24 12:55:25 |
Czytaj oryginał (ang.) |
| Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript |
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-20 20:38:03 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates |
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago. |
zacks.com |
2025-02-20 20:10:18 |
Czytaj oryginał (ang.) |
| Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance |
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m. |
prnewswire.com |
2025-02-20 18:01:00 |
Czytaj oryginał (ang.) |
| Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy |
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. |
prnewswire.com |
2025-02-19 18:52:00 |
Czytaj oryginał (ang.) |
| Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors |
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine instead of pursuing new acquisitions. |
reuters.com |
2025-02-19 10:04:15 |
Czytaj oryginał (ang.) |
| Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty |
Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines. |
benzinga.com |
2025-02-11 17:11:08 |
Czytaj oryginał (ang.) |
| Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025 |
EMERYVILLE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close. |
prnewswire.com |
2025-02-06 19:42:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade |
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-29 12:55:26 |
Czytaj oryginał (ang.) |
| Dynavax Advances Board Refreshment Program |
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting EMERYVILLE, Calif. , Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of Directors as part of its ongoing refreshment program: Emilio Emini, Ph.D. |
prnewswire.com |
2025-01-27 08:00:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know |
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-16 15:00:28 |
Czytaj oryginał (ang.) |
| Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights |
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 million contract with U.S. Department of Defense to advance plague vaccine program Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024 EMERYVILLE, Calif. , Jan. 13, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024. |
prnewswire.com |
2025-01-13 11:00:00 |
Czytaj oryginał (ang.) |
| Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-27 13:00:53 |
Czytaj oryginał (ang.) |
| Dynavax to Present at the 7th Annual Evercore HealthCONx Conference |
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. |
prnewswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies: What The Stock Buyback Means. What It Doesn't |
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also moved towards profitability and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally. |
seekingalpha.com |
2024-11-13 20:36:33 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why |
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-11 15:00:31 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know |
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-11 13:00:40 |
Czytaj oryginał (ang.) |
| Dynavax Announces $100 Million Accelerated Share Repurchase Program |
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. |
prnewswire.com |
2024-11-11 10:00:00 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates |
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2024-11-07 20:30:43 |
Czytaj oryginał (ang.) |
| Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates |
HEPLISAV-B ® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $ 200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today at 4:30 p.m. ET/1:30 p.m. |
prnewswire.com |
2024-11-07 18:02:00 |
Czytaj oryginał (ang.) |
| Dynavax Announces $200 Million Share Repurchase Program |
EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. |
prnewswire.com |
2024-11-07 18:01:00 |
Czytaj oryginał (ang.) |
| Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX) |
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Dynavax stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 1016. |
businesswire.com |
2024-11-06 15:10:00 |
Czytaj oryginał (ang.) |
| Dynavax Adopts Limited-Duration Stockholder Rights Plan |
EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). |
prnewswire.com |
2024-10-29 10:30:00 |
Czytaj oryginał (ang.) |
| Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 |
EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. |
prnewswire.com |
2024-10-24 20:10:00 |
Czytaj oryginał (ang.) |
| 3 'Repeatable' Biotech Trades |
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years. |
seekingalpha.com |
2024-09-25 16:46:35 |
Czytaj oryginał (ang.) |
| Dynavax Technologies: A Two Trick Pony Operating With A Single Trick |
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis. |
seekingalpha.com |
2024-08-23 08:32:03 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98% |
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-09 14:55:36 |
Czytaj oryginał (ang.) |
| Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript |
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Phil Nadeau - TD Cowen Jon Miller - Evercore Paul Choi - Goldman Sachs Roy Buchanan - JMP Securities Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. |
seekingalpha.com |
2024-08-07 00:54:11 |
Czytaj oryginał (ang.) |
| Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates |
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago. |
zacks.com |
2024-08-07 00:10:36 |
Czytaj oryginał (ang.) |
| Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates |
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 Conference call today at 4:30 p.m. ET/1:30 p.m. |
prnewswire.com |
2024-08-06 20:01:00 |
Czytaj oryginał (ang.) |
| Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 |
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close. |
prnewswire.com |
2024-07-23 20:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for July 9th |
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024. |
zacks.com |
2024-07-09 12:26:23 |
Czytaj oryginał (ang.) |